Success Stories: From RFE to Approval: NAILG Helped Internal Medicine Research Coordinator Earn EB-1A After Prior NIW Success
Client’s Testimonial:
“This makes me so happy! It has been a long journey, but I'm so happy to have you as my lawyers. Thank you for all the support and guidance. Thanks, thanks, thanks.”
On August 2nd, 2024, and April 11th, 2025, we received another EB-2 NIW (National Interest Waiver) and EB-1A (Alien of Extraordinary Ability) approvals for a Clinical Research Coordinator in the Field of Internal Medicine (Approval Notice).
General Field: Internal Medicine
Position at the Time of Case Filing: Clinical Research Coordinator
Country of Origin: Mexico
State of Residence at the Time of Filing: Texas
Approval Notice Date: August 2nd, 2024 (NIW) and April 11th, 2025 (EB1A)
Processing Time: 1 month, 23 days (NIW) (Premium Processing Requested), and 3 months, 3 days (EB1A) (Premium Processing Requested)
Case Summary:
Our client's journey through the U.S. immigration system has been defined by his unwavering dedication to internal medicine and by a legal team that recognized the true weight of his work. After the North America Immigration Law Group (NAILG) successfully helped him secure a National Interest Waiver (NIW) based on the national value of his research, he continued to cooperate with NAILG for his EB-1A petition, a natural next step in his immigration path as an individual of extraordinary ability.
But the EB-1A process came with its own challenges. Despite his impressive record, the petition received a Request for Evidence (RFE) - a moment that could have disrupted his momentum. Fortunately, with NAILG already deeply familiar with the strength and scope of his work, the team acted swiftly and strategically to build a compelling response.
Our client’s body of work reflects not only scholarly excellence but also practical contributions to the evolution of internal medicine. His research includes:
❖ The development of criteria for systematic reviews and meta-analyses,
❖ Investigations into novel trends in hepatic disease patients,
❖ Use of Point-of-Care Ultrasound (POCUS) to diagnose cardiac abnormalities,
❖ Examination of mental health and genetic factors in chronic illness patients in Mexico.
This work has led to:● 26 peer-reviewed journal articles, with 9 first-authored, 9 scientific abstracts, including 3 as first author, 4 first-authored book chapters
● 233 citations, with his work referenced by researchers in over 20 countries
Beyond publishing, he has made his mark in academic leadership. He has completed at least 79 peer reviews and serves on the editorial board of a peer-reviewed journal, highlighting the respect he commands among his peers.One of the recommendations submitted during his EB-1A petition underscored the broader implications of his work:
“To conclude, [client]’s focus on meta-analysis and its application to treating chronic diseases, as well as his publication portfolio, demonstrates how important his work is to the development of internal medicine. The many citations he has amassed over the years highlight the significance and impact of his research further. Halting his research would represent a major setback to innovation within the United States healthcare system and medical research efforts. As such, it is imperative that [client] be allowed to continue his research without interruption.”
NAILG’s legal team presented a meticulous and persuasive RFE response, reinforcing that our client meets the high threshold of sustained national and international acclaim required under the EB-1A category. Their deep understanding of both his case history and the complexities of medical research petitions played a pivotal role in the outcome.Ultimately, USCIS approved the EB-1A petition, marking not just a personal achievement for him but also a full-circle success story for a client whose immigration journey was supported every step of the way by NAILG.